Caas Capital Management LP Apellis Pharmaceuticals, Inc. Transaction History
Caas Capital Management LP
- $288 Million
- Q2 2024
Shares
2 transactions
Others Institutions Holding APLS
# of Institutions
299Shares Held
113MCall Options Held
5.21MPut Options Held
691K-
Wellington Management Group LLP Boston, MA16.4MShares$483 Million0.11% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.6MShares$342 Million15.74% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$327 Million5.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.81MShares$289 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$171 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.24B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...